Gary Goldstein, MD
Gastroenterology · Tucson, AZNPI 1952366791
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.2% of the total across 408 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 30.4% of the total.
Across 408 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Braintree Laboratories, Inc.$1K
- Fujifilm Healthcare Americas Corporation$581
- Nestle Healthcare Nutrition Inc.$549
- Aimmune Therapeutics, Inc.$534
- Phathom Pharmaceuticals, Inc.$530
- plus $3K from 22 others
Across 79 payments — averaging $2138.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$110K
- Takeda Pharmaceuticals U.S.A., Inc.$53K
- Braintree Laboratories, Inc.$6K
What the payments were for
- Food & beverage$7,57890%
- Education$70%
- Gifts$82010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 136 | $2,553 |
| Braintree Laboratories, Inc. | 30 | $1,074 |
| Fujifilm Healthcare Americas Corporation | 7 | $581 |
| Nestle Healthcare Nutrition Inc. | 40 | $549 |
| Aimmune Therapeutics, Inc. | 32 | $534 |
| Phathom Pharmaceuticals, Inc. | 30 | $530 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $402 |
| Johnson & Johnson | 23 | $327 |
| E.r. Squibb & Sons, L.L.C. | 2 | $250 |
| Sanofi | 9 | $206 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $195 |
| Medtronic | 2 | $190 |
| Gilead | 17 | $179 |
| Pfizer | 9 | $176 |
| Bristol Myers Squibb | 7 | $119 |
| Regeneron Healthcare Solutions, Inc. | 4 | $89 |
| Madrigal Pharmaceuticals | 3 | $72 |
| Lilly USA, LLC | 3 | $61 |
| Intercept Pharmaceuticals, Inc. | 3 | $53 |
| Enterra Medical, Inc. | 1 | $52 |
| Ardelyx, Inc. | 2 | $49 |
| Idorsia Pharmaceuticals US Inc | 3 | $49 |
| Novo Nordisk | 1 | $25 |
| Alfasigma USA, Inc. | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Lucid Diagnostics Inc. | 1 | $18 |
| Evoke Pharma, Inc. | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,405 in reported general payments places this provider in the 70th percentile of 355 gastroenterology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 14 | $113,827 |
| Xeljanz XrTofacitinib Citrate | 11 | $61,665 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 92 | $15,079 |
| Pantoprazole Sodium | 373 | $4,619 |
| Famotidine | 69 | $1,438 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 11 | $367 |
| Levofloxacin | 11 | $36 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aimmune Therapeutics, Inc.Zenpep | $534 | $113,82714 claims |
| Braintree Laboratories, Inc.Sutab | $1,074 | $15,07992 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 355 gastroenterology providers in Arizona.
Other gastroenterology in Tucson
- Joel BrillParadise Valley$847K
- Daniel MelineScottsdale$795K
- David FleischerScottsdale$410K
- Neil SharmaGilbert$405K
- Chirag TrivediSun City$400K
- David LeffMesa$377K
- Pankaj PasrichaScottsdale$304K
- Norio FukamiScottsdale$215K
- Toufic KachaamyScottsdale$210K
- Christina HaScottsdale$198K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.